Read by QxMD icon Read

Testicular cancer

Anna Hartmann Schmidt, Morten Høyer, Bent Frode Skov Jensen, Mads Agerbaek
BACKGROUND: Resection of residual masses after chemotherapy plays a crucial role in management of patients with germ cell tumours (GCTs). The extent of surgery is controversial and we present the experiences from Aarhus University Hospital over a 20-year period. The aim was to evaluate survival, complications, working ability and quality of life (QOL) following a limited surgical procedure performed to resect residual masses in non-seminomatous testicular cancer patients after chemotherapy...
March 14, 2018: Acta Oncologica
Darren R Feldman, Shirin Ardeshir-Rouhani-Fard, Patrick Monahan, Howard D Sesso, Chunkit Fung, Annalynn M Williams, Robert J Hamilton, David J Vaughn, Clair J Beard, Ryan Cook, Mohammad Abu Zaid, Steven E Lipshultz, Lawrence H Einhorn, Kevin C Oeffinger, Lois B Travis, Sophie D Fossa
BACKGROUND: Testicular cancer survivors (TCSs) are at increased risk of cardiovascular disease (CVD) after cisplatin-based chemotherapy (CBCT). Identifying at-risk survivors would allow early intervention, but risk prediction tools such as the Framingham Risk Score (FRS) have not been applied to TCSs given modern chemotherapy. METHODS: TCSs > 1 year post-CBCT were evaluated. Associations between FRS and clinical, socioeconomic, and lifestyle measures and treatment regimen (4 cycles, etoposide and cisplatin [EP × 4]); 3 or 4 cycles, bleomycin plus EP (BEP × 3, BEP × 4) were analyzed with general linear multivariable models...
February 5, 2018: Clinical Genitourinary Cancer
Haesol Lee, Dahae Lee, Ki Sung Kang, Ji Hoon Song, You-Kyoung Choi
Cisplatin is a well-known anticancer drug frequently used for treating solid tumors, including ovarian, testicular, bladder, and cervical tumors. However, usage of cisplatin has been limited because of its adverse effects, particularly nephrotoxicity. Therefore, the present study sought to investigate the protective effect of formononetin against cisplatin-induced cytotoxicity in LLC-PK1 pig kidney epithelial cells as well as the anticancer effect of cisplatin in three different human cervical cancer cell lines, including HeLa, SiHa, and CaSKi cells...
March 12, 2018: International Journal of Molecular Sciences
Ewa Rajpert-De Meyts, Rolf I Skotheim
No abstract text is available yet for this article.
March 9, 2018: European Urology
Faaiza Shahid, Zeba Farooqui, Farah Khan
Cisplatin (cis-diamminedichloroplatinum [II], CP) is most widely prescribed in chemotherapy and efficaciously treats diverse human cancers, with remission rates >90% in testicular cancers. However, clinical use of CP is associated with numerous untoward side effects, in particular, at the gastrointestinal level that reduces the therapeutic efficacy of CP and often results in withdrawal of its clinical usage in long term cancer chemotherapy. Substantial strides have been made to identify effective protective strategies against CP-induced nephrotoxicity, hepatotoxicity and ototoxicity...
March 9, 2018: European Journal of Pharmacology
Weijun Liang, Liuying Song, Zheng Peng, Yan Zou, Shengming Dai
BACKGROUND: A number of studies have investigated the association between androgenic alopecia (AGA) and cancer risk, but they have yielded inconsistent results. Therefore, this study was conducted to explore this controversial subject. METHODS: A literature database search was performed according to predefined criteria. An odds ratio (OR) or a hazard ratio (HR) with 95% confidence intervals (CIs) was retained to evaluate the relationship between the incidence of cancer or cancer-specific mortality and categories of AGA...
March 12, 2018: BMC Cancer
Rebecca Nash, Kevin C Ward, Ahmedin Jemal, David E Sandberg, Vin Tangpricha, Michael Goodman
BACKGROUND: Transgender people and persons with disorders of sex development (DSD) are two separate categories of gender minorities, each characterized by unique cancer risk factors. Although cancer registry data typically include only two categories of sex, registrars have the option of indicating that a patient is transgender or has a DSD. METHODS: Data for primary cancer cases in 46 states and the District of Columbia were obtained from the North American Association of Central Cancer Registries (NAACCR) database for the period 1995-2013...
March 9, 2018: Cancer Epidemiology
Nicola Nicolai, Davide Biasoni, Mario A Catanzaro, Maurizio Colecchia, Annalisa Trama
Germ-cell tumours (GCT) of the testis and penile squamous cell carcinoma (PeSCC) are a rare and a very rare uro-genital cancers, respectively. Both tumours are well defined entities in terms of management, where specific recommendations - in the form of continuously up-to-dated guide lines-are provided. Impact of these tumour is relevant. Testicular GCT affects young, healthy men at the beginning of their adult life. PeSCC affects older men, but a proportion of these patients are young and the personal consequences of the disease may be devastating...
February 14, 2018: European Journal of Surgical Oncology
Kazuya Sakai, Maky Ideta-Otsuka, Hirokatsu Saito, Yuki Hiradate, Kenshiro Hara, Katsuhide Igarashi, Kentaro Tanemura
Testicular toxicity is a frequent adverse effect of cancer chemotherapy that has no effective clinical biomarker. To find new biomarkers, we focused on epigenetic mechanisms in the male germline. We investigated the DNA methylation status of the male germline during testicular toxicity induced by doxorubicin (DXR), a widely used anticancer agent. We established mouse models of early stage testicular toxicity and testicular pre-toxicity by the administration of 0.2 mg/kg and 0.02 mg/kg DXR, respectively, twice weekly for 5 weeks...
March 7, 2018: Biochemical and Biophysical Research Communications
Mohammad Abu Zaid, Wambui G Gathirua-Mwangi, Chunkit Fung, Patrick O Monahan, Omar El-Charif, Annalynn M Williams, Darren R Feldman, Robert J Hamilton, David J Vaughn, Clair J Beard, Ryan Cook, Sandra K Althouse, Shirin Ardeshir-Rouhani-Fard, Paul C Dinh, Howard D Sesso, Lawrence H Einhorn, Sophie D Fossa, Lois B Travis
Background: Testicular cancer survivors (TCS) are at significantly increased risk for cardiovascular disease (CVD), with metabolic syndrome (MetS) an established risk factor. No study has addressed clinical and genetic MetS risk factors in North American TCS. Patients and Methods: TCS were aged <55 years at diagnosis and received first-line chemotherapy. Patients underwent physical examination, and had lipid panels, testosterone, and soluble cell adhesion molecule-1 (sICAM-1) evaluated. A single nucleotide polymorphism in rs523349 (5-α-reductase gene, SRD5A2 ), recently implicated in MetS risk, was genotyped...
March 2018: Journal of the National Comprehensive Cancer Network: JNCCN
Hendrik Borgmann, Johannes Salem, Martin Baunacke, Katharina Boehm, Christer Groeben, Marianne Schmid, Fabian P Siegel, Johannes Huber
OBJECTIVES: To quantify public and academic interest in the urological field using a novel new media-based methodology. METHODS: We systematically measured public and academic interest in 56 urological keywords and combined in nine subspecialties. Public interest was quantified as video views on YouTube. Academic interest was quantified as article citations using Microsoft Academic Search. The public-to-academic interest ratio was calculated for a comparison of subspecialties as well as for diseases and treatments...
March 8, 2018: International Journal of Urology: Official Journal of the Japanese Urological Association
Qingqiang Gao, Jianhuai Chen, Yutian Dai
BACKGROUND: In the past 20 years, the incidence of prostate cancer has risen rapidly. It has been ranked as the third most common malignant tumor of the male genitourinary system. Testicular metastasis is uncommon in prostate cancer. Most cases are incidentally found in the treatment of prostate cancer with orchiectomy. Therefore, we believed it was necessary to report the case of our patient with this disease. CASE PRESENTATION: We present a case of a 69-year-old Han Chinese man with a high total prostate-specific antigen level...
March 9, 2018: Journal of Medical Case Reports
Michael Kreiberg, Mikkel Bandak, Jakob Lauritsen, Julie Wang Skøtt, Nanna Borup Johansen, Mads Agerbaek, Niels Vilstrup Holm, Christoffer Johansen, Gedske Daugaard
The cohort was set up in order to analyze late effects in long-term testicular cancer survivors (TCS) and to contribute to the design of future follow-up programs addressing and potentially preventing late effects. Data for this cross-sectional study were collected between January 1, 2014, and December 31, 2016, among living Danish TCS and 60% agreed to participate in the cohort ( N  = 2,572). Mean time since testicular cancer (TC) diagnosis was 18 years (range 7-33) and mean age of participants was 53 years (range 25-95)...
2018: Frontiers in Oncology
Constantinos Roufas, Dimitrios Chasiotis, Anestis Makris, Christodoulos Efstathiades, Christos Dimopoulos, Apostolos Zaravinos
Background: Recently, immune-checkpoint blockade has shown striking clinical results in different cancer patients. However, a significant inter-individual and inter-tumor variability exists among different cancers. The expression of the toxins granzyme A (GZMA) and perforin 1 (PRF1), secreted by effector cytotoxic T cells and natural killer (NK) cells, were recently used as a denominator of the intratumoral immune cytolytic activity (CYT). These levels are significantly elevated upon CD8+ T-cell activation as well as during a productive clinical response against immune-checkpoint blockade therapies...
2018: Frontiers in Oncology
Tokuhiro Chano, Hiroko Kita, Sofia Avnet, Silvia Lemma, Nicola Baldini
In this study, we found that RAB39A , a member of the RAS oncogene family, was selectively expressed in cancer cells of different histotypes, by analyzing gene expression in human osteosarcoma cells and the cancer stem cells (CSCs) and by comparing them with normal cells through global transcriptomics and principal component analyses. We further validated RAB39A as a therapeutic target, by silencing its expression. The silencing impaired cancer stemness and spherogenic ability in vitro , as well as tumorigenesis in vivo ...
February 9, 2018: Oncotarget
Joshua L Pierce, A Lindsay Frazier, James F Amatruda
Germ cell tumors (GCTs) arising in infants, children, and adolescents present a set of special challenges. GCTs make up about 3% of malignancies in children aged 0-18 and nearly 15% of cancers in adolescents. Epidemiologic and molecular evidence suggests that GCTs in young children likely represent a distinct biologic group as compared to GCTs of older adolescents and adults. Despite this difference, pediatric GCTs are typically treated with cisplatin-based multiagent regimens similar to those used in adults...
2018: Advances in Urology
Axel John, André Baumgart, Thomas Worst, Julia Heinzelbecker
OBJECTIVE: The study aimed to calculate direct medical costs (DMC) during the first year of diagnosis and to evaluate the impact of guideline changes on treatment costs in clinical stage (CS) I testicular germ cell tumor (TGCT) patients in a German healthcare system. MATERIALS AND METHODS: Healthcare expenditures as DMC during the first year of diagnosis for 307 TGCT patients in CS I treated at our institution from 1987 to 2013 were calculated from the statutory health insurance perspective using patient level data...
March 7, 2018: Urologia Internationalis
Clare Akers
Testicular cancer is a highly treatable and curable malignancy. It typically affects men aged 15-35 years and is the most common malignancy in this age group. Nurses have an important role in assisting patients to cope with the diagnosis and understand the treatment options. It is also important for nurses to provide psychological support, because testicular cancer can have a significant effect on a man's fertility, sexuality and body image. This article examines the epidemiology and aetiology of the disease, together with its clinical presentation and treatment options...
March 7, 2018: Nursing Standard
Malene Roland Pedersen, Catherine Horsfield, Oliver Foot, Jan Lindebjerg, Palle Jørn Sloth Osther, Peter Vedsted, Ashish Chandra, Søren Rafael Rafaelsen, Henrik Møller
INTRODUCTION: Testicular cancer is the most common type of cancer in young Caucasian men. It has been suggested that testicular microlithiasis (TML) is a premalignant condition. This study's objective was to investigate TML histology prevalence in testicular cancer patients in two European populations. METHODS: We analysed archived histopathology orchiectomy specimens from 152 patients diagnosed with testicular cancer at Fredericia Hospital in Denmark from 2004 to 2014, and 106 patients diagnosed at St Thomas' Hospital in London from 2011 to 2015...
March 2018: Danish Medical Journal
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"